<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article article-type="letter"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">Br. J. Cancer</journal-id><journal-title-group><journal-title>British Journal of Cancer</journal-title></journal-title-group><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22814578</article-id><article-id pub-id-type="pmc">3419962</article-id><article-id pub-id-type="pii">bjc2012318</article-id><article-id pub-id-type="doi">10.1038/bjc.2012.318</article-id><article-categories><subj-group subj-group-type="heading"><subject>Short Communication</subject></subj-group></article-categories><title-group><article-title>A randomised study evaluating the use of pyridoxine to avoid capecitabine dose modifications</article-title><alt-title alt-title-type="running">Use of pyridoxine with capecitabine</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Corrie</surname><given-names>P G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="caf1">*</xref></contrib><contrib contrib-type="author"><name><surname>Bulusu</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>C B</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Armstrong</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bond</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Hardy</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Lao-Sirieix</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Parashar</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Ahmad</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Daniel</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Hill</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Wilson</surname><given-names>G</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Blesing</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Moody</surname><given-names>A M</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>McAdam</surname><given-names>K</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Osborne</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><aff id="aff1"><label>1</label><institution>Oncology Division, Addenbrooke's Hospital</institution>, Hills Road, Cambridge CB2 0QQ, <country>UK</country></aff><aff id="aff2"><label>2</label><institution>Primrose Oncology Centre, Bedford Hospital</institution>, Bedford MK42 9DJ, <country>UK</country></aff><aff id="aff3"><label>3</label><institution>Cambridge Cancer Trials Centre, Addenbrooke's Hospital</institution>, Cambridge CB2 0QQ, <country>UK</country></aff><aff id="aff4"><label>4</label><institution>Oncology Service, Queen Elizabeth Hospital, Kings Lynn</institution>, PE30 4ET, <country>UK</country></aff><aff id="aff5"><label>5</label><institution>Plymouth Oncology Centre, Derriford Hospital</institution>, Plymouth PL6 8DH, <country>UK</country></aff><aff id="aff6"><label>6</label><institution>Kent Oncology Centre, Maidstone Hospital</institution>, Maidstone ME16 9QQ, <country>UK</country></aff><aff id="aff7"><label>7</label><institution>Department of Medical Oncology, Christie Hospital</institution>, Manchester M20 4BX, <country>UK</country></aff><aff id="aff8"><label>8</label><institution>Oncology Service, Great Western Hospital</institution>, Marlborough Road, Swindon SN3 6BB, <country>UK</country></aff><aff id="aff9"><label>9</label><institution>Department of Oncology, West Suffolk Hospital, Bury St Edmunds</institution>, IP33 2QZ, <country>UK</country></aff><aff id="aff10"><label>10</label><institution>Haematology and Oncology Unit, Peterborough City Hospital</institution>, Peterborough PE3 9GZ, <country>UK</country></aff><aff id="aff11"><label>11</label><institution>Exeter Oncology Centre, Royal Devon &#x00026; Exeter Hospital</institution>, Exeter EX2 5DW, <country>UK</country></aff><aff id="aff12"><label>12</label><institution>Cambridge Clinical Trials Unit, Addenbrooke's Hospital</institution>, Cambridge CB2 0QQ, <country>UK</country></aff><aff id="aff13"><label>13</label><institution>MRC Biostatistics Unit Hub in Trials Methodology Research, Forvie Site</institution>, Cambridge CB2 0SR, <country>UK</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>E-mail: <email>pippa.corrie@addenbrookes.nhs.uk</email></corresp></author-notes><pub-date pub-type="ppub"><day>07</day><month>08</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>19</day><month>07</month><year>2012</year></pub-date><volume>107</volume><issue>4</issue><fpage>585</fpage><lpage>587</lpage><history><date date-type="received"><day>02</day><month>04</month><year>2012</year></date><date date-type="rev-recd"><day>20</day><month>06</month><year>2012</year></date><date date-type="accepted"><day>26</day><month>06</month><year>2012</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2012 Cancer Research UK</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>Cancer Research UK</copyright-holder></permissions><abstract><sec><title>Background:</title><p>Pyridoxine is frequently used to treat capecitabine-induced hand&#x02013;foot syndrome (HFS), although the evidence of benefit is lacking. We performed a randomised placebo-controlled trial to determine whether pyridoxine could avoid the need for capecitabine dose modifications and improve outcomes.</p></sec><sec><title>Methods:</title><p>A total of 106 patients planned for palliative single-agent capecitabine (53 in each arm, 65&#x00025;/&#x02009;35&#x00025; colorectal/breast cancer) were randomised to receive either concomitant pyridoxine (50&#x02009;mg po) or matching placebo three times daily.</p></sec><sec><title>Results:</title><p>Compared with placebo, pyridoxine use was associated with an increased rate of avoiding capecitabine dose modifications (37&#x00025; <italic>vs</italic> 23&#x00025;, relative risk 0.59, 95&#x00025; CI 0.29, 1.20, <italic>P</italic>=0.15) and fewer grade 3/4 HFS-related adverse events (9&#x00025; <italic>vs</italic> 17&#x00025;, odds ratio 0.51, 95&#x00025; CI 0.15&#x02013;1.6, <italic>P</italic>=0.26). Use of pyridoxine did not improve response rate or progression-free survival.</p></sec><sec><title>Conclusion:</title><p>Pyridoxine may reduce the need for capecitabine dose modifications and the incidence of severe HFS, but does not impact on antitumour effect.</p></sec></abstract><kwd-group><kwd>capecitabine</kwd><kwd>pyridoxine</kwd><kwd>hand&#x02013;foot syndrome</kwd><kwd>randomised trial</kwd></kwd-group></article-meta></front><body><p>Hand&#x02013;foot syndrome (HFS) is the most common adverse effect of capecitabine, with an incidence of 50&#x02013;60&#x00025; (<xref ref-type="bibr" rid="bib4">Gressett <italic>et al</italic>, 2006</xref>), and its occurrence can lead to delay or discontinuation of treatment. Pyridoxine is frequently used to treat HFS, but the evidence of benefit is both limited and controversial (<xref ref-type="bibr" rid="bib1">Beveridge <italic>et al</italic>, 1990</xref>; <xref ref-type="bibr" rid="bib7">Wiernik <italic>et al</italic>, 1992</xref>; <xref ref-type="bibr" rid="bib2">Chalermchai <italic>et al</italic>, 2010</xref>; <xref ref-type="bibr" rid="bib5">Kang <italic>et al</italic>, 2010</xref>). We performed a randomised placebo-controlled trial to determine whether pyridoxine could reduce the incidence of capecitabine dose modifications.</p><sec sec-type="materials|methods"><title>Materials and Methods</title><p>This multi-centre, randomised, double-blind, placebo-controlled NIHR portfolio phase 3 study was conducted at 10 UK sites. Patients with advanced colorectal or breast carcinoma receiving single agent capecitabine chemotherapy, ECOG performance status 0&#x02013;2, life expectancy &#x0003e;12 weeks and aged &#x0003e;18 years gave written consent before entering the study, which had research ethics approval. Patients were randomised 1&#x02009;:&#x02009;1 and stratified by cancer site (colorectal or breast) to receive either pyridoxine (50&#x02009;mg) or placebo orally three times daily commencing the same day that capecitabine chemotherapy was initiated. The capecitabine starting dose was planned to be 1250&#x02009;mg&#x02009;m<sup>&#x02212;2</sup> administered orally, twice daily, for 2 weeks followed by 7 days rest. Treatment continued until disease progression, toxicity or patient preference. After discontinuation, patients were followed up for 12 weeks.</p><sec><title>Efficacy and safety evaluation</title><p>The primary endpoint of this study was incidence of capecitabine dose modifications at or before 12 weeks of treatment. Secondary endpoints were the incidence of HFS, quality of life (using the EORTC QLQ-C30 version 3 questionnaire including the modules dedicated specifically to colorectal and breast cancer), response to chemotherapy and progression-free survival (PFS). The incidence of HFS and other adverse events was recorded using the NCI CTCAE version 3.0 every 3 weeks before each chemotherapy cycle and for 12 weeks after completing the last cycle of chemotherapy. Quality of life was assessed before each cycle of chemotherapy and 12 weeks after stopping treatment. Tumour response was measured every 12 weeks using RECIST criteria. Progression-free survival was measured from the date of randomisation until the first date documented of disease progression.</p></sec><sec><title>Statistical analysis</title><p>The study was designed to recruit 270 patients, to detect a reduction in the incidence of dose modification from 30 to 15&#x00025; with 80&#x00025; power and allowance for dropouts. The incidence of dose modifications was analysed using Kaplan&#x02013;Meier curves and the ratio of modification-free rates at 12 weeks of treatment were estimated using 95&#x00025; confidence intervals. Response rates at 12 weeks were analysed using logistic regression. Progression-free survival was analysed using Kaplan&#x02013;Meier curves and the hazard ratio comparing the instantaneous rate of progression estimated. All randomised patients were included in the analyses on an intention-to-treat basis.</p></sec></sec><sec sec-type="results"><title>Results</title><p>Between December 2004 and June 2009, 106 patients (53 in each arm) were recruited at 10 institutions in this NIHR portfolio trial. Slower than expected recruitment rate was due to decreasing numbers of patients being treated with capecitabine as a single agent and caused the study to close prematurely. Demographic comparison of both arms of the study identified no substantial imbalances, with median patient age 73 years, 64&#x00025; female, 65&#x00025; colorectal cancer and 93&#x00025; performance status 0&#x02013;1 (<xref rid="tbl1" ref-type="table">Table 1</xref>). Allowing for tablet strengths, 55&#x00025; of patients commenced full-dose capecitabine, 42&#x00025; started at a modified dose, whereas 3&#x00025; of patients did not start their planned treatment. Nine patients were excluded from the analysis: three patients never commenced treatment and seven patients had missing data regarding dosing. The remaining 97 patients were included in the analysis: 49 in the pyridoxine arm and 48 in the placebo arm. The median number of weeks on study was 15 for both arms, approximating to five cycles of three weekly chemotherapy. At 12 weeks, 29 patients on the placebo arm and 37 patients on the pyridoxine arm remained on-study.</p><p><xref rid="tbl2" ref-type="table">Table 2</xref> summarises all grade 3 and 4 AEs reported in both arms of the study. The combined incidence of HFS-related AEs (&#x02018;HFS' or &#x02018;rash hand foot skin reaction') showed a trend in favour of pyridoxine use: any grade was 51&#x00025; <italic>vs</italic> 53&#x00025; (odds ratio 0.93, 95&#x00025; CI 0.43&#x02013;2.0) whereas grade 3/4 was 9&#x00025; <italic>vs</italic> 17&#x00025; (odds ratio 0.51, 95&#x00025; CI 0.15&#x02013;1.6). There were no other differences in AEs between the two arms and no significant differences in quality of life. Summarising the Quality of Life QLQ-C30 using questions 29 and 30 (global health status and overall quality of life) observed on the second treatment cycle gave means (s.d.) of 66.1&#x00025; (18.3&#x00025;) and 62.5&#x00025; (22.6&#x00025;) for placebo (<italic>n</italic>=28) and pyridoxine (<italic>n</italic>=30), respectively; further exploratory analyses of different questions, subscales and time points revealed no differences.</p><p>At 12 weeks of treatment, the Kaplan&#x02013;Meier estimate of remaining free from dose modification was 37&#x00025; for patients receiving pyridoxine and 23&#x00025; in patients receiving placebo (<xref ref-type="fig" rid="fig1">Figure 1</xref>); relative risk ratio 0.59 (placebo/pyridoxine, 95&#x00025; CI 0.29, 1.20, <italic>P</italic>=0.152). Overall, pyridoxine had no significant effect on the objective response rate: 9 out of 46 responders on pyridoxine, and 9 out of 36 on placebo (placebo/pyridoxine odds ratio 1.37, 95&#x00025; CI 0.475&#x02013;3.96, <italic>P</italic>=0.56), but there was a trend towards pyridoxine decreasing PFS: median PFS durations of 7.4 months for pyridoxine and 9.9 months for placebo, hazard ratio 1.62 (pyridoxine/placebo 95&#x00025; CI 0.91&#x02013;2.88, log-rank <italic>P</italic>=0.095).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>Although not life threatening, HFS may give cause for capecitabine dose delay, reduction or discontinuation, with a theoretical concern regarding compromise of potential overall efficacy of the planned chemotherapy. The pathogenesis of HFS is not known, but has been variously treated with emollients, steroids and non-steroidal agents (<xref ref-type="bibr" rid="bib4">Gressett <italic>et al</italic>, 2006</xref>; <xref ref-type="bibr" rid="bib8">Zhang <italic>et al</italic>, 2012</xref>). Because HFS resembles a rat disease, acrodynia, caused by pyridoxine deficiency, treatment with pyrodixine was proposed (<xref ref-type="bibr" rid="bib6">Vukelja <italic>et al</italic>, 1989</xref>; <xref ref-type="bibr" rid="bib3">Fabian <italic>et al</italic>, 1990</xref>). A small randomised study of 26 patients reported amelioration of HFS with pyridoxine 100&#x02009;mg daily compared with placebo in patients receiving continuous infusional 5-Fluorouracil (<xref ref-type="bibr" rid="bib1">Beveridge <italic>et al</italic>, 1990</xref>). Since then, two further randomised trials have been undertaken in SE Asian populations only. The first study of 389 patients reported that pyridoxine taken at 200&#x02009;mg daily did not prevent HFS compared with placebo (<xref ref-type="bibr" rid="bib5">Kang <italic>et al</italic>, 2010</xref>). The second smaller study of 56 patients compared 200 <italic>vs</italic> 400&#x02009;mg concomitant pyridoxine and reported a trend in favour of improved HFS incidence and time to event with the higher pyridoxine dose (<xref ref-type="bibr" rid="bib2">Chalermchai <italic>et al</italic>, 2010</xref>). In this UK study, 150&#x02009;mg daily pyridoxine appeared to reduce the incidence of grade 3/4 HFS and the need for capecitabine dose modifications, although this did not translate into an improvement in outcome from chemotherapy itself: the trend towards poorer PFS in the pyridoxine arm was not statistically significant. It was not possible to detect any significant change in overall or specific elements of patient quality of life, using the QLQ-C30 instrument and the disease-specific modules.</p><p>Whether pyridoxine might in fact negatively influence chemotherapy efficacy is intriguing, although not conclusive. In their study of 200 <italic>vs</italic> 400&#x02009;mg concomitant pyridoxine, <xref ref-type="bibr" rid="bib2">Chalermchai <italic>et al</italic> (2010)</xref> reported significantly lower tumour responses to capecitabine at the higher pyridoxine dose level, whereas its use in advanced ovarian cancer was previously reported to reduce the duration of response to treatment with hexamethylamine plus cisplatin (<xref ref-type="bibr" rid="bib7">Wiernik <italic>et al</italic>, 1992</xref>). Pyridoxine has in the past been considered an inexpensive method of avoiding the need to reduce capecitabine dosing. Pyridoxine has in the past been considered an inexpensive method of avoiding the need to reduce capecitabine dosing. Based on the CAPP-IT study results, its use as routine prophylaxis of HFS is not recommended.</p></sec></body><back><ack><p>This study was supported by the West Anglia Cancer Research Network and Cambridge Cancer Trials Centre.</p></ack><ref-list><ref id="bib1"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beveridge</surname><given-names>RA</given-names></name><name><surname>Kales</surname><given-names>AN</given-names></name><name><surname>Binder</surname><given-names>RA</given-names></name><name><surname>Miller</surname><given-names>JA</given-names></name><name><surname>Virts</surname><given-names>SG</given-names></name></person-group><year>1990</year><article-title>Pyridoxine (B6) and amelioration of hand/foot syndrome</article-title><source>Proc Am Soc Clin Oncol</source><volume>9</volume><fpage>102a</fpage>(abstr 393)</mixed-citation></ref><ref id="bib2"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalermchai</surname><given-names>T</given-names></name><name><surname>Tantiphlachiva</surname><given-names>K</given-names></name><name><surname>Suwanrusme</surname><given-names>H</given-names></name><name><surname>Voravud</surname><given-names>N</given-names></name><name><surname>Sriuranpong</surname><given-names>V</given-names></name></person-group><year>2010</year><article-title>Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia</article-title><source>Asia-Pacific J Clin Oncol</source><volume>6</volume><fpage>155</fpage><lpage>160</lpage></mixed-citation></ref><ref id="bib3"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fabian</surname><given-names>CJ</given-names></name><name><surname>Molina</surname><given-names>R</given-names></name><name><surname>Slavik</surname><given-names>M</given-names></name><name><surname>Dahlberg</surname><given-names>S</given-names></name><name><surname>Giri</surname><given-names>S</given-names></name><name><surname>Stephens</surname><given-names>R</given-names></name></person-group><year>1990</year><article-title>Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion</article-title><source>Invest New Drugs</source><volume>8</volume><fpage>57</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">2345070</pub-id></mixed-citation></ref><ref id="bib4"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gressett</surname><given-names>SM</given-names></name><name><surname>Stanford</surname><given-names>BL</given-names></name><name><surname>Hardwicke</surname><given-names>F</given-names></name></person-group><year>2006</year><article-title>Management of hand-foot syndrome induced by capecitabine</article-title><source>J Oncol Pharm Pract</source><volume>12</volume><fpage>131</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">17022868</pub-id></mixed-citation></ref><ref id="bib5"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kang</surname><given-names>YK</given-names></name><name><surname>Lee</surname><given-names>SS</given-names></name><name><surname>Yoon</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Chun</surname><given-names>YJ</given-names></name><name><surname>Kim</surname><given-names>MS</given-names></name><name><surname>Ryu</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>HM</given-names></name><name><surname>Lee</surname><given-names>JL</given-names></name><name><surname>Kim</surname><given-names>TW</given-names></name></person-group><year>2010</year><article-title>Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study</article-title><source>J Clin Oncol</source><volume>28</volume><fpage>3824</fpage><lpage>3829</lpage><pub-id pub-id-type="pmid">20625131</pub-id></mixed-citation></ref><ref id="bib6"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vukelja</surname><given-names>SJ</given-names></name><name><surname>Lombardo</surname><given-names>FA</given-names></name><name><surname>James</surname><given-names>WD</given-names></name><name><surname>Weiss</surname><given-names>RB</given-names></name></person-group><year>1989</year><article-title>Pyridoxine for the palmar-plantar erythrodysesthesia syndrome</article-title><source>Ann Intern Med</source><volume>111</volume><fpage>688</fpage><lpage>689</lpage><pub-id pub-id-type="pmid">2529807</pub-id></mixed-citation></ref><ref id="bib7"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiernik</surname><given-names>PH</given-names></name><name><surname>Yeap</surname><given-names>B</given-names></name><name><surname>Vogl</surname><given-names>SE</given-names></name><name><surname>Kaplan</surname><given-names>BH</given-names></name><name><surname>Comis</surname><given-names>RL</given-names></name><name><surname>Falkson</surname><given-names>G</given-names></name><name><surname>Davis</surname><given-names>TE</given-names></name><name><surname>Fazzini</surname><given-names>E</given-names></name><name><surname>Cheuvart</surname><given-names>B</given-names></name><name><surname>Horton</surname><given-names>J</given-names></name></person-group><year>1992</year><article-title>Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group</article-title><source>Cancer Invest</source><volume>10</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1735009</pub-id></mixed-citation></ref><ref id="bib8"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>RX</given-names></name><name><surname>Wu</surname><given-names>XJ</given-names></name><name><surname>Wan</surname><given-names>DS</given-names></name><name><surname>Lu</surname><given-names>ZH</given-names></name><name><surname>Kong</surname><given-names>LH</given-names></name><name><surname>Pan</surname><given-names>ZZ</given-names></name><name><surname>Chen</surname><given-names>G</given-names></name></person-group><year>2012</year><article-title>Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial</article-title><source>Annals Oncol</source><volume>23</volume><fpage>1348</fpage><lpage>1353</lpage></mixed-citation></ref></ref-list></back><floats-group><fig id="fig1"><label>Figure 1</label><caption><p>Kaplan-Meier estimates of the time to first dose modification.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bjc2012318f1"/></fig><table-wrap id="tbl1"><label>Table 1</label><caption><title>Clinical characteristics</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>Variable</bold></th><th align="center" valign="top" charoff="50"><bold>Statistic</bold></th><th align="center" valign="top" charoff="50"><bold>Placebo (</bold><italic><bold>N</bold></italic><bold>=53)</bold></th><th align="center" valign="top" charoff="50"><bold>Pyridoxine (</bold><italic><bold>N</bold></italic><bold>=53)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">Age (years)</td><td align="center" valign="top" charoff="50">Mean (s.d.)</td><td align="char" valign="top" char="(" charoff="50">70 (10)</td><td align="char" valign="top" char="(" charoff="50">70 (9)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Median</td><td align="center" valign="top" charoff="50">73</td><td align="center" valign="top" charoff="50">72</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Min, Max</td><td align="center" valign="top" charoff="50">42, 87</td><td align="center" valign="top" charoff="50">43, 84</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Cancer type</td><td align="center" valign="top" charoff="50">Breast</td><td align="char" valign="top" char="(" charoff="50">34.0&#x00025; (18/53)</td><td align="char" valign="top" char="(" charoff="50">37.7&#x00025; (20/53)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Colorectal</td><td align="char" valign="top" char="(" charoff="50">66.0&#x00025; (35/53)</td><td align="char" valign="top" char="(" charoff="50">62.3&#x00025; (33/53)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Performance status</td><td align="center" valign="top" charoff="50">1</td><td align="char" valign="top" char="(" charoff="50">85.7&#x00025; (24/28)</td><td align="char" valign="top" char="(" charoff="50">88.0&#x00025; (22/25)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">2</td><td align="char" valign="top" char="(" charoff="50">14.3&#x00025; (4/28)</td><td align="char" valign="top" char="(" charoff="50">12.0&#x00025; (3/25)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Gender</td><td align="center" valign="top" charoff="50">Male</td><td align="char" valign="top" char="(" charoff="50">37.7&#x00025; (20/53)</td><td align="char" valign="top" char="(" charoff="50">37.7&#x00025; (20/53)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">Female</td><td align="char" valign="top" char="(" charoff="50">62.3&#x00025; (33/53)</td><td align="char" valign="top" char="(" charoff="50">62.3&#x00025; (33/53)</td></tr><tr><td align="left" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td><td align="center" valign="top" charoff="50">&#x000a0;</td></tr><tr><td align="left" valign="top" charoff="50">Capecitabine</td><td align="center" valign="top" charoff="50">92&#x02013;100&#x00025;</td><td align="char" valign="top" char="(" charoff="50">54.7&#x00025; (29/53)</td><td align="char" valign="top" char="(" charoff="50">56.6&#x00025; (30/53)</td></tr><tr><td align="left" valign="top" charoff="50">starting dose</td><td align="center" valign="top" charoff="50">64&#x02013;80&#x00025;</td><td align="char" valign="top" char="(" charoff="50">41.5&#x00025; (22/53)</td><td align="char" valign="top" char="(" charoff="50">41.5&#x00025; (22/53)</td></tr><tr><td align="left" valign="top" charoff="50">(&#x00025; full dose)</td><td align="center" valign="top" charoff="50">No treatment</td><td align="char" valign="top" char="(" charoff="50">3.8&#x00025; (2/53)</td><td align="char" valign="top" char="(" charoff="50">1.9&#x00025; (1/53)</td></tr></tbody></table></table-wrap><table-wrap id="tbl2"><label>Table 2</label><caption><title>Summary of all grade 3 and 4 AEs reported</title></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="char" char="("/><col align="char" char="("/></colgroup><thead valign="bottom"><tr><th align="left" valign="top" charoff="50"><bold>AEs grade 3/4</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Placebo (</bold><italic><bold>N</bold></italic><bold>=53) (&#x00025;)</bold></th><th align="center" valign="top" char="(" charoff="50"><bold>Pyridoxine (</bold><italic><bold>N</bold></italic><bold>=53) (&#x00025;)</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" charoff="50">HFS</td><td align="char" valign="top" char="(" charoff="50">9 (17)</td><td align="char" valign="top" char="(" charoff="50">5 (9)</td></tr><tr><td align="left" valign="top" charoff="50">Diarrhoea</td><td align="char" valign="top" char="(" charoff="50">6 (11)</td><td align="char" valign="top" char="(" charoff="50">1 (2)</td></tr><tr><td align="left" valign="top" charoff="50">Pain</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td><td align="char" valign="top" char="(" charoff="50">3 (6)</td></tr><tr><td align="left" valign="top" charoff="50">Anorexia</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td><td align="char" valign="top" char="(" charoff="50">0 (0)</td></tr><tr><td align="left" valign="top" charoff="50">Dyspnoea</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td><td align="char" valign="top" char="(" charoff="50">0 (0)</td></tr><tr><td align="left" valign="top" charoff="50">Fatigue</td><td align="char" valign="top" char="(" charoff="50">1 (2)</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td></tr><tr><td align="left" valign="top" charoff="50">Nausea</td><td align="char" valign="top" char="(" charoff="50">2 (2)</td><td align="char" valign="top" char="(" charoff="50">2 (4)</td></tr></tbody></table><table-wrap-foot><fn id="t2-fn1"><p>Abbreviations: AEs=adverse events; HFS=hand&#x02013;foot syndrome.</p></fn></table-wrap-foot></table-wrap></floats-group></article>